Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours
Mené sur 309 patients atteints d'une tumeur neuroendocrine gastro-entéro-pancréatique (durée médiane de suivi : 27,5 mois), cet essai multicentrique de phase III compare l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'évérolimus et du [177Lu]Lu-édotréotide (Lutétium-177-édotréotide)
Treatment sequencing in advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs) remains a major unmet clinical need.1 Although somatostatin receptor-positive, well differentiated GEP-NETs often follow a somewhat indolent course, disease progression eventually requires treatment decisions that balance tumour control, toxicity, quality of life, and the preservation of future therapeutic options.
The Lancet , commentaire, 2026